Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib Maintenance in ES-SCLC
NCT04901754Phase 2
Key facts
- Status
- Unknown
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Countries
- 1
- Sponsor
- Henan Cancer Hospital
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Conditions
- Small Cell Lung Cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in Small Cell Lung Cancer (SCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Camrelizumab + Apatinib
Camrelizumab 200 mg IV every 3 weeks plus Apatinib 250 mg orally once daily.
03
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT04901754.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901754.